Back to Agenda
Session 1: Introduction of the Windsor Framework – What will be the impact?
Session Chair(s)
Elspeth McIntosh, MBA, RN
Director
Castle Pharmacovigilance Ltd, United Kingdom
This interactive session will delve into the key aspects of the Windsor Framework and its potential impact on pharmacovigilance process: what will be the potential implications for QPPVs and NCPs? As the pharmacovigilance changes associated with the new framework are in development, we have an opportunity for industry and regulators to discuss this topic face-to-face. Participants are encouraged to bring their questions and concerns for an engaging discussion. This session aims to provide valuable insights into activities involved in this hot topic.
Also, stay up-to-date with the latest changes and updates from the MHRA, from internal restructures to PV updates.
Speaker(s)
Changes and Updates from the MHRA
Phil Tregunno
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Deputy Director - Patient Safety Monitoring
Changes and Updates from the MHRA
Stephanie Millican, PhD, MSc
MHRA, United Kingdom
Deputy Director Benefit Risk Evaluation, Safety and Surveillance
Have an account?